

## DAFTAR PUSTAKA

- Bari, A., Marcheselli, L., Sacchi, S., Marcheselli, R., Pozzi, S., Ferri, P., *et al.*, 2010. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. *Ann. Oncol.* 21: 1486–1491. doi:10.1093/annonc/mdp531
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., & Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68: 394–424. doi:10.3322/caac.21492
- Bremnes, R.M., Busund, L.-T., Kilv  r, T.L., Andersen, S., Richardsen, E., Paulsen, E.E., *et al.*, 2016. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer. *J. Thorac. Oncol.* 11: 789–800. doi:10.1016/j.jtho.2016.01.015
- Chen, J.-H., Zhai, E.-T., Yuan, Y.-J., Wu, K.-M., Xu, J.-B., Peng, J.-J., *et al.*, 2017. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. *World J. Gastroenterol.* 23: 6261. doi:10.3748/wjg.v23.i34.6261
- Chen, Y., Neelapu, S., Feng, L., Bi, W., Yang, T.-H., Wang, M., *et al.*, 2016. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum  $\beta$ 2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. *Br. J. Haematol.* 175: 290–299. doi:10.1111/bjh.14237
- Chen, Y., Zhang, Z., Fang, Q., & Jian, H., 2019. Prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma: a meta-analysis. *Cancer Cell Int.* 19: 245. doi:10.1186/s12935-019-0962-3
- Coccaro, N., Anelli, L., Zagaria, A., Perrone, T., Specchia, G., & Albano, F., 2020. Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? *Cancers (Basel)*. 12: 185. doi:10.3390/cancers12010185
- Coiffier, B., & Karlin, 2013. Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. *Onco. Targets. Ther.* 6: 289. doi:10.2147/OTT.S42574
- Coiffier, B., Lepage, E., Bri  re, J., Herbrecht, R., Tilly, H., Bouabdallah, R., *et al.*, 2002. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. *N. Engl. J. Med.* 346: 235–242. doi:10.1056/NEJMoa011795
- Dong, M., Shi, Y., Yang, J., Zhou, Q., Lian, Y., Wang, D., *et al.*, 2020. Prognostic

and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. *Ther. Adv. Med. Oncol.* 12: 175883592093742. doi:10.1177/1758835920937425

Feng, J., Wang, Z., Guo, X., Chen, Y., Cheng, Y., & Tang, Y., 2012. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. *Int. J. Hematol.* 95: 143–148. doi:10.1007/s12185-011-0993-6

Fisher, R., Gaynor, E., Dahlberg, S., Oken, M., Grogan, T., Mize, E., *et al.*, 1993. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hdgin's Lymphoma. *N. Engl. J. Med.* 322: 2012.

Fu, H., Zheng, J., Cai, J., Zeng, K., Yao, J., Chen, L., *et al.*, 2018. Systemic Immune-Inflammation Index (SII) is Useful to Predict Survival Outcomes in Patients After Liver Transplantation for Hepatocellular Carcinoma within Hangzhou Criteria. *Cell. Physiol. Biochem.* 47: 293–301. doi:10.1159/000489807

Gonzalez, H., Hagerling, C., & Werb, Z., 2018. Roles of the immune system in cancer: from tumor initiation to metastatic progression. *Genes Dev.* 32: 1267–1284. doi:10.1101/gad.314617.118

Gouveia, G.R., Siqueira, S.A.C., & Pereira, J., 2012. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. *Rev. Bras. Hematol. Hemoter.* 34: 447–451. doi:10.5581/1516-8484.20120111

Guo, W., Cai, S., Zhang, F., Shao, F., Zhang, G., Zhou, Y., *et al.*, 2019. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. *Thorac. Cancer* 10: 761–768. doi:10.1111/1759-7714.12995

Harkins, R.A., Chang, A., Patel, S.P., Lee, M.J., Goldstein, J.S., Merdan, S., *et al.*, 2019. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. *Expert Rev. Hematol.* 12: 959–973. doi:10.1080/17474086.2019.1660159

Hirahara, N., Matsubara, T., Fujii, Y., Kaji, S., Kawabata, Y., Hyakudomi, R., *et al.*, 2020. Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer. *Oncotarget* 11: 2625–2635. doi:10.18632/oncotarget.27653

Horvat, M., Zadnik, V., Južnič Šetina, T., Boltežar, L., Pahole Goličnik, J., Novaković, S., *et al.*, 2018. Diffuse large B-cell lymphoma: 10 year's real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. *Oncol. Lett.* 15: 3602–3609. doi:10.3892/ol.2018.7774

- Hung, M.-H., Yu, Y.-B., Hsiao, L.-T., Hong, Y.-C., Liu, J.-H., Gau, J.-P., *et al.*, 2013. Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure. *J. Chinese Med. Assoc.* 76: 195–200. doi:10.1016/j.jcma.2012.12.003
- Kalafati, L., Mitroulis, I., Verginis, P., Chavakis, T., & Kourtzelis, I., 2020. Neutrophils as Orchestrators in Tumor Development and Metastasis Formation. *Front. Oncol.* 10: 1–9. doi:10.3389/fonc.2020.581457
- Kim, D.-Y., Song, M.-K., Chung, J.-S., Shin, H.-J., Yang, D.H., Lim, S.-N., *et al.*, 2019. Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma. *BLOOD Res.* 54: 244–252. doi:10.5045/br.2019.54.4.244
- Li, C., Tian, W., Zhao, F., Li, M., Ye, Q., Wei, Y., *et al.*, 2018. Systemic immune-inflammation index, SII, for prognosis of elderly patients with newly diagnosed tumors. *Oncotarget* 9: 35293–35299. doi:10.18632/oncotarget.24293
- Liu, T., Ye, F., Li, Y., & Liu, A., 2021. Comparison and exploration of the prognostic value of the advanced lung cancer inflammation index, prognostic nutritional index, and systemic immune-inflammation index in newly diagnosed diffuse large B-cell lymphoma. *Ann. Palliat. Med.* 10: 9650–9659. doi:10.21037/apm-21-2067
- Lodhi, N., Tun, M., Nagpal, P., Inamdar, A.A., Ayoub, N.M., Siyam, N., *et al.*, 2020. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. *Oncotarget* 11: 4045–4073. doi:10.18632/oncotarget.27785
- Manfroï, B., McKee, T., Mayol, J.F., Tabruyn, S., Moret, S., Villiers, C., *et al.*, 2017. CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. *Cancer Res.* 77: 1097–1107. doi:10.1158/0008-5472.CAN-16-0786
- Manfroï, B., Moreaux, J., Righini, C., Ghiringhelli, F., Sturm, N., & Huard, B., 2018. Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients. *Blood Cancer J.* 8: 66. doi:10.1038/s41408-018-0099-y
- Menter, T., & Tzankov, A., 2019. Lymphomas and Their Microenvironment: A Multifaceted Relationship. *Pathobiology* 86: 225–236. doi:10.1159/000502912
- Mirili, C., Paydas, S., Kapukaya, T.K., & Yılmaz, A., 2019. Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. *Biomark. Med.* 13: 1565–1575. doi:10.2217/bmm-2019-0303

- Mu, S., Ai, L., Fan, F., Qin, Y., Sun, C., & Hu, Y., 2018. Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose–response meta-analysis. *Cancer Cell Int.* 18: 119. doi:10.1186/s12935-018-0609-9
- Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., *et al.*, 2008. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol.* 9: 105–116. doi:10.1016/S1470-2045(08)70002-0
- Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., *et al.*, 2006. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol.* 7: 379–391. doi:10.1016/S1470-2045(06)70664-7
- Qiu, L., Zheng, H., & Zhao, X., 2019. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. *BMC Cancer* 19: 273. doi:10.1186/s12885-019-5466-y
- Rovira, J., Valera, A., Colomo, L., Setoain, X., Rodríguez, S., Martínez-Trillos, A., *et al.*, 2015. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. *Ann. Hematol.* 94: 803–812. doi:10.1007/s00277-014-2271-1
- Salles, G., Barrett, M., Foà, R., Maurer, J., O’Brien, S., Valente, N., *et al.*, 2017. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. *Adv. Ther.* 34: 2232–2273. doi:10.1007/s12325-017-0612-x
- Sehn, L.H., & Salles, G., 2021. Diffuse Large B-Cell Lymphoma. *N. Engl. J. Med.* 384: 842–858. doi:10.1056/NEJMra2027612
- Song, M.-K., Chung, J.-S., Seol, Y.-M., Kim, S.-G., Shin, H.-J., Choi, Y.-J., *et al.*, 2010. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. *Ann. Oncol.* 21: 140–144. doi:10.1093/annonc/mdp505
- Sonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., *et al.*, 1995. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. *J. Clin. Oncol.* 13: 2530–2539. doi:10.1200/JCO.1995.13.10.2530
- Sukswai, N., Lyapichev, K., Khoury, J.D., & Medeiros, L.J., 2020. Diffuse large

- B-cell lymphoma variants: an update. *Pathology* 52: 53–67. doi:10.1016/j.pathol.2019.08.013
- Tamma, R., Ranieri, G., Ingravallo, G., Annese, T., Oranger, A., Gaudio, F., *et al.*, 2020. Inflammatory Cells in Diffuse Large B Cell Lymphoma. *J. Clin. Med.* 9: 2418. doi:10.3390/jcm9082418
- Tilly, H., Gomes da Silva, M., Vitolo, U., Jack, A., Meignan, M., Lopez-Guillermo, A., *et al.*, 2015. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 26: v116–v125. doi:10.1093/annonc/mdv304
- Uribe-Querol, E., & Rosales, C., 2015. Neutrophils in Cancer: Two Sides of the Same Coin. *J. Immunol. Res.* 2015: 983698. doi:10.1155/2015/983698
- Vaidya, R., & Witzig, T.E., 2014. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. *Ann. Oncol.* 25: 2124–2133. doi:10.1093/annonc/mdu109
- Wang, S., Ma, Y., Sun, L., Shi, Y., Jiang, S., Yu, K., *et al.*, 2018. Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma. *Biomed Res. Int.* 2018: 1–8. doi:10.1155/2018/9651254
- Wang, Z., Zhang, J., Luo, S., & Zhao, X., 2021. Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma. *Front. Oncol.* 11: 1–10. doi:10.3389/fonc.2021.655259
- Wilcox, R.A., Ristow, K., Habermann, T.M., Inwards, D.J., Micallef, I.N.M., Johnston, P.B., *et al.*, 2011. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. *Leukemia* 25: 1502–1509. doi:10.1038/leu.2011.112
- Wu, X.-B., Hou, S.-L., & Liu, H., 2021. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients. *World J. Clin. Cases* 9: 9825–9834. doi:10.12998/wjcc.v9.i32.9825
- Xiong, S., Dong, L., & Cheng, L., 2021. Neutrophils in cancer carcinogenesis and metastasis. *J. Hematol. Oncol.* 14: 1–17. doi:10.1186/s13045-021-01187-y
- Yan, M., & Jurasz, P., 2016. The role of platelets in the tumor microenvironment: From solid tumors to leukemia. *Biochim. Biophys. Acta - Mol. Cell Res.* 1863: 392–400. doi:10.1016/j.bbamcr.2015.07.008
- Yang, J., Guo, X., Hao, J., Dong, Y., Zhang, T., & Ma, X., 2019. The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma. *Front. Oncol.* 9. doi:10.3389/fonc.2019.01392

- Yang, R., Chang, Q., Meng, X., Gao, N., & Wang, W., 2018. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis. *J. Cancer* 9: 3295–3302. doi:10.7150/jca.25691
- Zhang, Y., Chen, B., Wang, L., Wang, R., & Yang, X., 2019. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer. *Medicine (Baltimore)*. 98: e13788. doi:10.1097/MD.00000000000013788
- Zhang, Y., Sun, Y., & Zhang, Q., 2020. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. *Cancer Cell Int.* 20: 224. doi:10.1186/s12935-020-01308-6
- Zhong, J.-H., Huang, D.-H., & Chen, Z.-Y., 2017. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. *Oncotarget* 8: 75381–75388.